Interventional cardiology is a medical specialty well known for embracing promising new device technologies, and as a result, the field has progressed over the years well beyond its initial focus on coronary balloon angioplasty and stenting. The specialty’s unique mix of open-mindedness and evidence-based clinical rigor has enabled it to serve as a breeding ground for a number of novel and very lucrative device markets, beginning a decade ago with drug-eluting stents (DES) and continuing today with the two latest pivotal advances in the field: transcatheter aortic valve implantation (TAVI) and transcatheter renal denervation for the treatment of resistant hypertension – both of which appear to be truly disruptive technologies with blockbuster market potential. (See Also see "As TAVI Advances, Adjunctive Devices Multiply" - Medtech Insight, 16 December, 2011. and Also see "Renal Denervation Sparks Device Market Gold Rush" - Medtech Insight, 25 May, 2012..)
Drug-Coated Balloons Fuel Multibillion-Dollar Hopes
With a total market potential estimated in the multibillion-dollar range, the drug-coated balloon opportunity is attracting a growing list of competitors, including several leading multinational cardiovascular device companies that have entered the space via recent acquisitions. DCBs still need to prove their worth in large, long-term clinical trials, but the ultimate proving point for DCBs could center on cost: if they can offer an effective treatment option that is significantly less expensive than existing devices, DCBs may provide a compelling economic argument.
More from Archive
More from Medtech Insight
Through this partnership, data stored in LibreView – Abbott’s cloud-based diabetes data management system – can automatically flow into Epic, allowing clinicians using Epic to view a patient’s CGM data before, during and after visits without toggling between systems or requesting manual uploads.
Back-to-back meetings at LSX? No time to attend the innovator showcase? Here is what you might have missed from medtech innovators at the LSX World Congress Europe on 29 April.
HistoSonics, which developed a noninvasive technology to destroy tumor cells, reports 90% local tumor control at 12-month follow-up in the #HOPE4Liver Trial. The Edison System, cleared by the US FDA in late 2023, is also being evaluated for kidney and pancreatic tumors. CEO Mike Blue said the medtech is financially secure but watching public markets as it considers an IPO.